Why lantus

Do not transfer the insulin from the pen into a syringe. Never share an injection pen or syringe with another person, even if the needle has been changed. Sharing these devices can allow infections or disease to pass from one person to another. You may have low blood sugar hypoglycemia and feel very hungry, dizzy, irritable, confused, anxious, or shaky. To quickly treat hypoglycemia, eat or drink a fast-acting source of sugar fruit juice, hard candy, crackers, raisins, or non-diet soda.

Your doctor may prescribe a glucagon injection kit in case you have severe hypoglycemia. Be sure your family or close friends know how to give you this injection in an emergency. Also watch for signs of high blood sugar hyperglycemia such as increased thirst or urination. Blood sugar levels can be affected by stress, illness, surgery, exercise, alcohol use, or skipping meals.

Ask your doctor before changing your dose or medication schedule. Keep this medicine in its original container protected from heat and light. Do not draw insulin from a vial into a syringe until you are ready to give an injection. Do not freeze insulin or store it near the cooling element in a refrigerator. Throw away any insulin that has been frozen. Do not use the medicine if it looks cloudy, has changed colors, or has any particles in it.

Call your pharmacist for new medicine. Wear a diabetes medical alert tag in case of emergency. Any medical care provider who treats you should know that you have diabetes. Use a needle and syringe only once and then place them in a puncture-proof "sharps" container. Follow state or local laws about how to dispose of this container. It also contains 3 mL of solution with units of insulin per mL. Lantus and Levemir are both given as an injection just under your skin a subcutaneous injection.

Lantus and Levemir both contain long-acting insulins. Therefore, both medications can cause very similar side effects. Below are examples of these side effects. This list contains examples of more common side effects that can occur with both Lantus and Levemir when taken individually :. This list contains examples of serious side effects that can occur with both Lantus and Levemir when taken individually :.

Lantus and Levemir have different FDA-approved uses. A review of studies found that Lantus and Levemir were equally effective at improving blood sugar levels in adults with type 1 diabetes. There was also no difference in the risk of low blood sugar episodes between the two drugs. The review of studies also looked at people with type 2 diabetes. The analysis found no difference between Lantus and Levemir in improving blood sugar levels or in the rates of low blood sugar episodes.

Lantus and Levemir are both brand-name drugs. There are currently no generic forms of either drug. Brand-name medications usually cost more than generics. According to estimates on GoodRx. Here we look at how Lantus and Basaglar are alike and different. The Food and Drug Administration FDA has approved both Lantus and Basaglar to improve blood sugar levels in children ages 6 and older and adults with type 1 diabetes. Both drugs are also approved to improve blood sugar levels in adults with type 2 diabetes.

Lantus and Basaglar both contain insulin glargine. Basaglar is called an insulin follow-on drug to Lantus. This means that Basaglar is a biologic product made from parts of living organisms that is highly similar to Lantus. The FDA considers follow-on drugs to be just as effective and safe as the original brand-name version of the drug. Lantus and Basaglar both come as a liquid solution in a disposable, prefilled pen. Lantus and Basaglar are both given as an injection just under your skin a subcutaneous injection.

The drugs are typically given once a day. This list contains examples of more common side effects that can occur with both Lantus and Basaglar when taken individually :. This list contains examples of serious side effects that can occur with both Lantus and Basaglar when taken individually :. Lantus and Basaglar are both FDA-approved to lower blood sugar levels in adults and children with type 1 diabetes.

They are also both approved to lower blood sugar levels in adults with type 2 diabetes. The use of Lantus and Basaglar for type 1 diabetes and type 2 diabetes has been directly compared.

In a 1-year study , Lantus and Basaglar were found to be equally effective at improving blood sugar levels in people with type 1 diabetes. The people had similar rates of hypoglycemia low blood sugar , allergic reactions, and changes in weight. In this study, both drugs were used in combination with mealtime insulin.

In another clinical study , Lantus and Basaglar helped control blood sugar levels about equally well in people with type 2 diabetes. The drugs were used in combination with oral taken by mouth medications for six months. Lantus and Basaglar are both brand-name drugs.

Here we look at how Lantus and Tresiba are alike and different. Lantus is approved for people ages 6 years and older with type 1 diabetes and for adults with type 2 diabetes. It comes in two forms:. Both Lantus and Tresiba are given as an injection just under your skin a subcutaneous injection. Lantus and Tresiba both contain long-acting insulins. This list contains examples of more common side effects that can occur with both Lantus and Tresiba when taken individually :.

This list contains examples of serious side effects that can occur with both Lantus and Tresiba when taken individually :. Lantus and Tresiba are both FDA-approved to improve blood sugar levels in people with type 1 and type 2 diabetes.

The use of Lantus and Tresiba in treating type 1 diabetes has been directly compared in several clinical studies. In a pooled analysis of these studies, Lantus and Tresiba were found to be equally effective at improving blood sugar levels in adults with type 1 diabetes.

Another clinical study found no difference in blood sugar level improvements between Lantus and Tresiba in children with type 1 diabetes. The use of Lantus and Tresiba in treating type 2 diabetes has also been directly compared. A pooled analysis of nine studies found that Lantus and Tresiba improved blood sugar levels to a similar degree in adults with type 2 diabetes.

However, there was a lower risk of severe low blood sugar and low blood sugar at night with Tresiba. Lantus and Tresiba are both brand-name drugs.

Lantus may be used with other diabetes medications, including other injectable drugs or medications taken by mouth. People with type 1 diabetes will need to take Lantus along with a mealtime insulin.

A mealtime insulin is needed to control spikes in blood sugar that occur after eating. People with type 2 diabetes will also likely need to take other diabetes medications besides Lantus. There are several different types of injectable or oral taken by mouth medications that your doctor may prescribe. These drugs lower your blood sugar further and help prevent serious complications, such as nerve damage.

Typically, your doctor will start you on a low dosage. Your doctor will ultimately prescribe the smallest dosage that provides the desired effect. The following information describes dosages that are commonly used or recommended. However, be sure to take the dosage your doctor prescribes for you. Your doctor will determine the best dosage to suit your needs. Note : Making any changes to your insulin treatment plan could increase your risk for both hypoglycemia low blood sugar levels and hyperglycemia high blood sugar levels.

Lantus comes as a liquid solution inside vials and disposable, prefilled pens. Each vial of Lantus contains 10 milliliters mL of solution. Each mL contains units of insulin glargine. This strength is also called Lantus U The disposable, prefilled pen of Lantus is called SoloStar. Each pen contains 3 mL of solution. There are units of insulin glargine in each mL.

That adds up to a total of units of insulin per Lantus SoloStar pen. And keep in mind that each form of Lantus takes a different needle type. The Lantus vial and Lantus SoloStar pen are both meant to be used more than once. This is known as being multi-dose.

The number of times will be different for each person, depending on your dosage. You can use the vials and pens for up to 28 days after you open them. After that time, you should dispose of the vial or pen, even if it still contains some of the drug. If you have type 1 diabetes , the starting dose of Lantus is generally about one-third of your total daily insulin dose. Your total daily insulin dose is based on your weight. It typically ranges from 0. There are about 2.

For example, a lb man weighs about 68 kg. If his doctor prescribes 0. Lantus to be discontinued Tuesday, 16 June What does this mean for users of Lantus? The current stocks you have are fine to keep using until the expiry date on your medication box.

The expiry date 28 days after opening of the pen you are using stays the same. You do not need to throw out or exchange the insulin you have in stock.

When you get your next supply, the pharmacist can substitute the brand for a replacement long-acting insulin. You have two options for a replacement insulin, Optisulin or Semglee: Optisulin is another brand of Insulin Glargine made by Sanofi. It is manufactured by the same processes. It has the same active and inactive components as Lantus. You will be able to replace Lantus with Optisulin at the same dose. The pre-filled disposable pen device is very similar.

You will notice a small change in colour and name of the pen device. The Optisulin pen fill cartridges will fit into your existing reusable pen device. Never reuse needles or syringes and never share needles, syringes, or pens. If you are using an insulin pen, always remove the needle right after you inject your dose.

Discard needles and syringes in a puncture-resistant container. Ask your doctor or pharmacist how to dispose of the puncture-resistant container. Do not dilute insulin glargine products and do not mix insulin glargine products with any other type of insulin.

You can inject your insulin glargine in your upper arm, thigh, or stomach. Never inject insulin glargine into a vein or muscle. Change rotate the injection site within the chosen area with each dose; try to avoid injecting the same site more often than once every 1 to 2 weeks. Always look at your insulin glargine product before you inject it. It should be clear and colorless. Do not use your insulin glargine product if it is colored, cloudy, or contains solid particles, or if the expiration date on the bottle has passed.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. Be sure to follow all exercise and dietary recommendations made by your doctor or dietitian.

It is important to eat a healthful diet and to eat about the same amounts of the same kinds of food at about the same times each day. Skipping or delaying meals or changing the amount or kind of food you eat can cause problems with your blood sugar control. Before you start using an insulin glargine product, ask your doctor what to do if you forget to use a dose or if you accidentally use an extra dose.

Write these directions down so you can refer to them later. Insulin glargine products may cause other side effects. Call your doctor if you have any unusual problems while using this medication.

Keep this medication in the container it came in and out of reach of children. Store unopened insulin glargine product vials and pens in the refrigerator. Never allow insulin glargine products to freeze; do not use insulin glargine that has been frozen and thawed. Unopened refrigerated insulin glargine products can be stored until the date shown on the company's label.

If a refrigerator is unavailable for example, when on vacation , store the vials or pens at room temperature and away from direct sunlight and extreme heat. Unrefrigerated vials or pens can be used within 28 days; after that time they must be discarded. Opened vials can be stored for 28 days at room temperature or in the refrigerator. Opened pens must be stored at room temperature and may be used for up to 28 days after the first use.